The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global anticoagulants market reached a value of US$ 34.0 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 60.8 Billion by 2027, exhibiting a CAGR of 10.2% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.
Blood clots form when blood thickens and forms a semi-solid mass in any part of the body. This causes serious problems, such as stroke, heart attack, pulmonary embolism, transient ischemic attacks, and deep vein thrombosis (DVT). As a result, doctors around the world are prescribing anticoagulant drugs to people who are at a high risk of clot formation. These drugs help in thinning blood, preventing or reducing blood clotting, and prolonging the clotting time. They are usually available in capsule or tablet form, including warfarin, rivaroxaban, dabigatran and apixaban.
Recent research indicates that hypercoagulability in individuals affected by the coronavirus disease (COVID-19) pandemic can be one of the leading causes of mortality worldwide. As a result, its surging cases are positively influencing the demand for anticoagulant drugs to treat the thrombotic condition among critically ill or hospitalized patients. Moreover, certain risk factors, such as extended sitting, smoking, trauma, blood disorders, and autoimmune diseases, can cause blood clotting in different parts of the body. This, in confluence with the increasing prevalence of human immunodeficiency virus (HIV), hepatitis C, Lyme disease, obesity, cancer, and chronic inflammation, represents another significant factor strengthening the growth of the market. Apart from this, the growing aging population across the globe is resulting in the escalating demand for surgical services. Surgeries often require prolonged bed rest, which, in turn, increases the risk of blood clotting and the overall sales of anticoagulant drugs. Furthermore, the improving diagnosis rates and the escalating demand for target therapeutics are fueling the market growth. The emergence of online pharmacies is also driving the demand for anticoagulant drugs around the world.
IMARC Group provides an analysis of the key trends in each sub-segment of the global anticoagulants market report, along with forecasts for growth at the global and regional level from 2022-2027. Our report has categorized the market based on drug class, route of administration, distribution channel and application.
Breakup by Drug Class:
Breakup by Route of Administration:
Breakup by Distribution Channel:
Breakup by Application:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Alexion Pharmaceuticals Inc, Aspen Holdings, Bayer AG, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Daiichi Sankyo Company Limited, Dr. Reddy’s Laboratories Ltd, GlaxoSmithKline plc, Johnson & Johnson Private Limited, Pfizer Inc. and Sanofi.
|Base Year of the Analysis||2021|
|Segment Coverage||Drug Class, Route of Administration, Distribution Channel, Application, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||Alexion Pharmaceuticals Inc, Aspen Holdings, Bayer AG, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Daiichi Sankyo Company Limited, Dr. Reddy’s Laboratories Ltd, GlaxoSmithKline plc, Johnson & Johnson Private Limited, Pfizer Inc. and Sanofi|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at